|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2011-3-18
|
|
pubmed:abstractText |
Surgical intervention is the primary treatment for early-stage renal cell carcinoma (RCC), but alone it has limited benefit in patients with metastatic disease. The advent of targeted agents for RCC has improved the outcome in these patients, and there is increasing interest in exploring the efficacy and safety of these agents in combination with surgery in both early and advanced disease.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1873-7560
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2010 European Association of Urology. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
58
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
819-28
|
|
pubmed:meshHeading |
pubmed-meshheading:20828919-Carcinoma, Renal Cell,
pubmed-meshheading:20828919-Chemotherapy, Adjuvant,
pubmed-meshheading:20828919-Clinical Trials as Topic,
pubmed-meshheading:20828919-Disease-Free Survival,
pubmed-meshheading:20828919-Evidence-Based Medicine,
pubmed-meshheading:20828919-Humans,
pubmed-meshheading:20828919-Kidney Neoplasms,
pubmed-meshheading:20828919-Molecular Targeted Therapy,
pubmed-meshheading:20828919-Neoadjuvant Therapy,
pubmed-meshheading:20828919-Nephrectomy,
pubmed-meshheading:20828919-Risk Assessment,
pubmed-meshheading:20828919-Survival Rate,
pubmed-meshheading:20828919-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.
|
|
pubmed:affiliation |
Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. a.bex@nki.nl
|
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|
